Sangamo Therapeutics, Inc. (SGMO)
0.4515
0.00 (0.00%)
USD |
NASDAQ |
Jan 13, 16:00
0.447
0.00 (0.00%)
After-Hours: 18:09
Sangamo Therapeutics Research and Development Expense (Quarterly): 28.69M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arcturus Therapeutics Holdings, Inc. | 19.38M |
| AIM ImmunoTech, Inc. | 0.525M |
| Perspective Therapeutics, Inc. | 19.56M |
| Protalix Biotherapeutics, Inc. | 4.467M |
| Armata Pharmaceuticals, Inc. | 5.824M |